Colloidal gold nanoparticles are targeting probes to improve varlitinib delivery into cancer\ncells. The nanoconjugates were designed by the bioconjugation of pegylated gold nanoparticles with\nvarlitinib via carbodiimide-mediated cross-linking and characterized by infrared and X-ray photoelectron\nspectroscopy. The drug release response shows an initial delay and a complete drug release after 72 h\nis detected. In vitro experiments with MIA PaCa-2 cells corroborate that PEGAuNPsVarl conjugates\nincrease the varlitinib toxic effect at very low concentrations (IC50 = 80 nM) if compared with varlitinib\nalone (IC50 = 259 nM). Our results acknowledge a decrease of drug side effects in normal cells and an\nenhancement of drug efficacy against to the pancreatic cancer cells reported.
Loading....